Clinical trials: Allergic Disease
Healthy, Asthma
A Study in Healthy Subjects and Mild Asthmatics to Investigate Pharmacokinetics of AZD5423 When Administered in Different Ways
A study in healthy subjects and mild asthmatics to investigate Pharmacokinetics of AZD5423 when administered in different ways.
- Trial name
- NCT01310322
- Testing
- AZD5423
- Where
- United Kingdom
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Allergy, Rhinitis
Safety Clinical Trial With Depigopid 50% Grasses/50% Olea Europaea(2000DPP/ml) or Depigoid 50% Grasses/50% Parietaria Judaica(2000DPP/ml).
The primary objective of this study is to evaluate the safety and tolerance of a rush build up administration of Depigoid forte pollen and the first maintenance dose administered 4 weeks later.
- Conditions
- Allergy, Rhinitis, Rhinoconjunctivitis, Seasonal Asthma
- Trial name
- NCT01734265
- Testing
- Depigoid 50% Grasses/50% Olea europaea (2000DPP/ml), Depigoid 50% Grasses/50% Parietaria judaica (2000DPP/ml)
- Where
- 4 sites in Spain
- Volunteers
- 63 people
- Sponsor
- Laboratorios Leti, S.L.
Dermatitis
Study of the Safety and Efficacy of Tacrolimus Ointment in Treating Chronic Allergic Contact Dermatitis
A study of subjects with a known nickel allergy comparing Tacrolimus to placebo, both associated with nickel patches to determine the safety and efficacy of treating Chronic Allergic Contact Dermatitis with Tacrolimus Ointment
- Trial name
- NCT00667056
- Testing
- tacrolimus ointment
- Where
- 10 sites in United States
- Volunteers
- 98 people
- Sponsor
- Astellas Pharma Inc
Allergic Conjunctivitis
Efficacy Investigation Study of Olopatadine Hydrochloride Ophthalmic Solution Using OHIO Chamber in Patients With Seasonal Allergic Rhinitis (SAR)
To evaluate the efficacy of olopatadine 0.1% using the OHIO Chamber in patients with seasonal allergic conjunctivitis.
- Trial name
- NCT00818805
- Testing
- Olopatadine 0.1%, Tranilast 0.5%
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Alcon Research
Allergic Rhinitis Due to Pollen, Allergic Rhinitis With Asthma
Interaction Between Air Pollution, Pollens and Allergic Rhinitis
Seasonal allergic rhinitis has multiple consequences: sleep disturbances, fatigue, depressed mood, impaired quality of life and productivity, and co-morbid conditions such as asthma, which affects one third of AR patients.
- Trial name
- MISTRAL (NCT05007327)
- Testing
- Exposure to pollen and air pollution
- Where
- France
- Volunteers
- 1,215 people
- Sponsor
- MASK-air SAS
Allergic Rhinitis
Safety and Tolerability of Single and Multiple Doses of VAK694 in Healthy and Atopic Subjects
This study will evaluate the safety and tolerability of single and multiple doses of VAK694 in healthy volunteers and otherwise healthy volunteers with a history of allergies.
- Trial name
- NCT00620230
- Testing
- NVP-VAK694
- Where
- United States
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Novartis
Invasive Pulmonary Aspergillosis, Allergic Bronchopulmonary Aspergillosis
Voriconazole Inhalation Powder for the Treatment of Pulmonary Aspergillosis
Voriconazole Inhalation Powder is available on an expanded access basis to patients with pulmonary aspergillosis for up to 12 weeks.
- Conditions
- Invasive Pulmonary Aspergillosis, Allergic Bronchopulmonary Aspergillosis, Chronic Pulmonary Aspergillosis, Aspergillus Tracheobronchitis
- Trial name
- NCT05897294
- Testing
- Voriconazole Inhalation Powder
- Sponsor
- TFF Pharmaceuticals, Inc.
Rhinitis, Allergic, Perennial
Investigation of the Efficacy and Safety of Concomitant Administration of Ciclesonide Nasal Spray and Azelastine Nasal Spray in Patients (18 Years or Older) With Perennial Allergic Rhinitis (PAR) Not Adequately Controlled on an Intranasal Corticosteroid or Antihistamine Monotherapy (BY9010/M1-490)
The primary objective of this study is to evaluate the efficacy of the concomitant administration of ciclesonide nasal spray and azelastine nasal spray versus ciclesonide nasal spray alone in patients (18 years or older) with…
- Trial name
- NCT00806754
- Testing
- Ciclesonide nasal spray + Azelastine
- Where
- 35 sites in United States
- Volunteers
- 340 people
- Sponsor
- AstraZeneca
Asthma, House Dust Mite Allergy
Dose Ranging Study of SLIT Tablets of House Dust Mite Allergen Extracts (HDM) in Adults With HDM-associated Allergic Asthma
The purpose of this study is to investigate the efficacy and safety of different doses of sublingual tablets of house dust mite allergen extracts as compared to placebo in adults with house dust mite-associated allergic asthma.
- Trial name
- NCT01930461
- Testing
- SLIT tablets of HDM allergen extracts, 3 different doses (A), SLIT tablets of HDM allergen extracts, 3 different doses (B), SLIT tablets of HDM allergen extracts, 3 different doses (C)
- Where
- 5 sites in France, Germany and 1 more
- Volunteers
- 386 people
- Sponsor
- Stallergenes Greer
Allergy Testing, Peanut Allergies
BÜHLMANN BAT (Basophil Activation Test) in Allergy Diagnosis (Exploratory Pilot Study)
The goal of this exploratory pilot study is to generate early data needed for future validation studies of the automated BÜHLMANN BAT (Basophil activation test) assay.
- Conditions
- Allergy Testing, Peanut Allergies, Venom Allergy, House Dust Mite Allergy
- Trial name
- NCT07596303
- Where
- Germany
- Volunteers
- 38 people
- Sponsor
- Bühlmann Laboratories AG
Prostate Cancer
The Plenaxis® Experience Study
Praecis is currently conducting a 2000 patient Experience Study; this is a Phase IV commitment postmarketing safety study in the Food and Drug Administration (FDA) indicated population of patients receiving Plenaxis®.
- Trial name
- NCT00103623
- Testing
- Plenaxis
- Where
- 60 sites in United States
- Volunteers
- 2,000 people
- Sponsor
- PRAECIS Pharmaceuticals Inc.
Seasonal Allergic Rhinitis
Comparative Safety and Efficacy of Two Steroid Treatments in the Relief of the Symptoms of Seasonal Allergic Rhinitis
To compare safety and efficacy of Perrigo's steroid drug product compared with an FDA approved steroid drug product in the treatment of subjects with seasonal allergic rhinitis.
- Trial name
- NCT02230696
- Testing
- Azelastine Hydrochloride/Fluticasone Propionate Nasal Spray
- Where
- 30 sites in United States
- Volunteers
- 951 people
- Sponsor
- Padagis LLC
Seasonal Allergic Rhinitis
Clinical Trial of TQH2722 Injection in Patients With Seasonal Allergic Rhinitis
To evaluate TQH2722 injection in all patients receiving background treatment with mometasone furoate nasal spray (MFNS) and loratadine.
- Trial name
- NCT06760182
- Testing
- TQH2722 injection
- Where
- 30 sites in China
- Volunteers
- 169 people
- Sponsor
- Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Perennial Allergic Rhinitis (PAR)
A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis (PREPARED-1)
The main purpose of this study is to evaluate the efficacy and safety of lebrikizumab in adult participants with perennial allergic rhinitis. Participants can expect study participation to last up to 29.5 months.
- Trial name
- NCT06339008
- Testing
- LY3650150, Standard therapy for INCS
- Where
- 74 sites in United States, Belgium and 4 more
- Volunteers
- 450 people
- Sponsor
- Eli Lilly and Company
Asthma
Bronchodilator Effects and Safety of Glycopyrronium Bromide (25 ug and 50 ug o.d.) in Asthma
The purpose of this trial is to characterize the bronchodilator effects and safety of 25 ug and 50 ug o.d. NVA237 (glycopyrronium bromide) doses compared to placebo in asthma patients
- Trial name
- NCT03137784
- Testing
- NVA237 (glycopyrronium bromide)
- Where
- 21 sites in United States, Belgium and 4 more
- Volunteers
- 148 people
- Sponsor
- Novartis Pharmaceuticals
Perennial Allergic Rhinitis
Efficacy and Safety of Concomitant Montelukast Sodium and Levocetirizine Dihydrochloride in Perennial Allergic Rhinitis (PAR) Patients
The purpose of this study is to demonstrate that the efficacy of Concomitant Montelukast Sodium and Levocetirizine Dihydrochloride is superior to that of Levocetirizine and Montelukast monotherapies and to compare the safety and…
- Trial name
- NCT01640535
- Testing
- Montelukast + Levocetirizine, Levocetirizine, Montelukast
- Where
- South Korea
- Volunteers
- 283 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Allergic Conjunctivitis
Evaluation of Efficacy of Ophthalmic Solution in Seasonal Allergic Conjunctivitis
The purpose of this summary is to evaluate the efficacy and safety of R89674 0.025% ophthalmic solution compared with placebo or an active control in subjects with seasonal allergic conjunctivitis
- Trial name
- NCT00364091
- Testing
- R89674 0.025% ophthalmic solution
- Where
- 6 sites in United States
- Volunteers
- 365 people
- Sponsor
- Vistakon Pharmaceuticals
Rhinitis, Allergic, Seasonal, Hay Fever
To Assess the Safety and Efficacy of Ciclesonide, Applied as a Nasal Spray in the Treatment of Seasonal Allergic Rhinitis (BY9010/M1-401)
The primary objective of this study is to demonstrate the efficacy of ciclesonide applied as a nasal spray once daily in patients with SAR. The secondary objectives are to evaluate Quality-of-Life and safety.
- Trial name
- NCT00659841
- Testing
- Ciclesonide
- Where
- 6 sites in United States
- Volunteers
- 302 people
- Sponsor
- AstraZeneca
Allergic Rhinitis
Clinical Trial Of The Effectiveness Of The Product Cloratadd D (Loratadine + Pseudoephedrine Sulfate) Produced By The Laboratory EMS S/A, Compared To The Drug Claritin D Produced By Schering-Plough S/A, In Patients With Allergic Rhinitis
The primary objective of this study is to evaluate the clinical efficacy of the drug Cloratadd D ® (loratadine + pseudoephedrine sulfate - EMS S/A) compared to the drug Claritin D ® (loratadine + pseudoephedrine sulfate …
- Trial name
- NCT01055756
- Testing
- Loratadine + Pseudoephedrine sulfate
- Where
- Brazil
- Sponsor
- Azidus Brasil
Asthma
Efficacy and Safety Study of QAW039 in Patients With Severe Asthma Inadequately Controlled With Standard of Care Asthma Treatment.
This study aimed to determine the efficacy and safety of QAW039 150 mg and QAW039 450 mg, compared with placebo, when added to GINA (Global Initiative for Asthma) steps 4 and 5 standard-of- care (SoC) asthma therapy (GINA 2016)…
- Trial name
- NCT02555683
- Testing
- QAW039
- Where
- 234 sites in United States, Argentina and 25 more
- Volunteers
- 894 people
- Sponsor
- Novartis Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.